Torrent Pharmaceuticals Ltd Q4 FY26 Results Analysis: Revenue Surges 42%, PAT Falls 27% on Acquisition Costs

Torrent Pharmaceuticals Ltd's Q4 FY26 numbers came in mixed, with revenue of Rs. 4,197.00 Cr (+42.00% YoY) and PAT growth of -22.00% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Torrent Pharma reported strong 42% YoY revenue growth in Q4 FY26, but reported PAT fell 27% due to heavy acquisition-related costs from the JB Pharma purchase. The underlying Base Business continues to deliver solid 15-16% revenue growth with stable EBITDA margins of ~32.7%, though the elevated debt of Rs.14,798 crore and integration costs will weigh on reported earnings in the near term. Management's path to deleveraging (Net Debt/EBITDA of 1-1.1x by FY28) and the planned merger to eliminate minority interest are key catalysts to watch.

Key Investment Insights

Key Positives

• Consolidated revenue grew 42% YoY to Rs.4,197 crore in Q4 FY26, and Base Business (ex-JB Pharma) grew 16% YoY to Rs.3,424 crore.
• FY26 Base Business revenue grew 15% YoY to Rs.13,207 crore, meeting the implied guidance range.
• Base Business EBITDA margin for FY26 was 32.7%, within 20 bps of management's stated minimum target of 32.9%.
• Reported EBITDA grew 41% YoY to Rs.1,356 crore in Q4 FY26, with stable margin of 32.3% despite acquisition-related cost drag.
• Operating cash flow of Rs.3,023 crore was 1.41x reported PAT and 0.66x EBITDA, indicating solid earnings quality.
• Board recommended enabling approval for QIP/debt instruments up to Rs.5,000 crore for future growth and deleveraging.
• Normalized PAT for Q4 FY26 was Rs.724 crore, up from reported Rs.364 crore, stripping acquisition-related one-time costs.
• FY26 Base Business PAT grew 22% YoY to Rs.2,340 crore, showing strong underlying profitability.
• The company has ICRA AA+ (Stable) credit rating, and management targets Net Debt/EBITDA of 1-1.1x by FY28.

Risk Factors

• Reported PAT declined 27% YoY in Q4 FY26 due to Rs.257 crore PPA depreciation, Rs.200 crore acquisition interest, and Rs.66 crore exceptional items.
• Total debt surged from Rs.3,026 crore to Rs.14,798 crore after the JB Pharma acquisition, with Debt/Equity rising to 1.76x from 0.40x.
• Finance costs rose 321% YoY to Rs.236 crore, and D&A rose 153% to Rs.508 crore in Q4 FY26, both acquisition-driven.
• Germany supply disruption continues, with Q3 revenue -6% constant currency and no recovery visible in Q4 statutory results.
• US business run-rate of $144 million annualized is well below the $200 million target, requiring ~30% growth to meet the milestone.
• NCI now represents 52.3% of consolidated equity (Rs.9,196 crore), meaning a large portion of JB Pharma's earnings belong to minority holders until the merger completes.
• Interest coverage ratio fell to 4.97x in Q4 FY26 from 13.66x a year ago, reflecting higher leverage.
• R&D spend of 4.65% of FY26 revenue was slightly below management's guidance of 5-5.5%.